ALK, a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in activated oncogenic fusion forms, most common being the nucleophosmin ALK in anaplastic large-cell lymphomas and paediatric cancer as well as neuroendocrine tumors [21]. Here, ALK is linked to childhood malignant neoplasm.